Share Email Print

Journal of Biomedical Optics

Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents
Author(s): Molly A. Brewer; Urs Utzinger; Yang Li; Edward Neely Atkinson; William Satterfield; Nelly Auersperg; Rebecca R. Richards-Kortum; Michele Follen; Robert C. Bast
Format Member Price Non-Member Price
PDF $20.00 $25.00

Paper Abstract

The objective of this study was to compare the effects of chemopreventive agents on natural fluorescence emission of ovarian cells in a cell culture and in a primate model as a feasibility trial to monitor drug activity. Methods: Fluorescence emission spectra were collected from normal (NOE) and immortalized ovarian surface epithelial cells at 290, 360, and 450 nm excitation. Redox potentials were calculated and compared to % apoptosis and cell survival. Fluorescence emission spectra were collected from 18 female rhesus macaques receiving fenretinide [N-(-hydroxyphenyl)retinamide (4- HPR)] orally and/or oral contraceptive pills (OCP) or no medication. Fluorescence intensities and redox ratios were compared using a twotailed Student’s t test. Results: Apoptosis and cell survival correlated with fluorescence emission consistent with metabolically active proteins [flavin adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide (NAD(P)H)] and the resulting redox ratio in cells grown with 4-HPR. The 4-HPR consistently inhibited cell survival in a dose dependent manner. Degree of correlation varied between different cell lines. In primates receiving 4-HPR, fluorescence emission was increased at 450 nm excitation, 550 nm emission consistent with FAD presence, whereas those receiving OCP showed decreased emission at 350 nm excitation, 450 nm emission consistent with decreased NAD(P)H presence. Redox ratios were increased by both drugs. Conclusions: Fluorescence intensity and redox ratio appear to be altered by 4-HPR treatment in vivo and in cell culture and by OCP in vivo. Fluorescence intensity may be useful to monitor chemopreventive agents in clinical trials.

Paper Details

Date Published: 1 January 2002
PDF: 7 pages
J. Biomed. Opt. 7(1) doi: 10.1117/1.1427672
Published in: Journal of Biomedical Optics Volume 7, Issue 1
Show Author Affiliations
Molly A. Brewer, Arizona Cancer Ctr (United States)
Urs Utzinger, Univ. of Texas/Austin (United States)
Yang Li, Univ of Texas M D Anderson Cancer Ctr (United States)
Edward Neely Atkinson, University of Texas M D Anderson Cancer Ctr (United States)
William Satterfield, Univ of Texas M D Anderson Cancer Ctr (United States)
Nelly Auersperg, B.C. Women's Hospital & Health Ctr (Canada)
Rebecca R. Richards-Kortum, Univ. of Texas/Austin (United States)
Michele Follen, Univ. of Texas (United States)
Robert C. Bast, Univ. of Texas M.D. Anderson Cancer Ctr. (United States)

© SPIE. Terms of Use
Back to Top